- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 5, 2025
Emerging Company Profile
Bambusa: Combining validated I&I targets in bispecifics to broaden efficacy
With $105M in venture funding, Bambusa has moved quickly towards the clinic with bispecifics in-licensed from antibody powerhouse Biotheus
BioCentury | Sep 13, 2024
Finance
Trio of first-day pops may bode well for biotech IPO window
With three biotechs trading up after NASDAQ debuts, sustained positive performance could further open window
BioCentury | Aug 26, 2024
Finance
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue
Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
BioCentury | Dec 5, 2023
Product Development
Dec. 4 Quick Takes: EyePoint’s data for Eylea competitor drive big gain
Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech
BioCentury | Nov 3, 2023
Discovery & Translation
Dimeric IgA targets intracellular oncogenes; plus taRNAs and more
BioCentury’s roundup of translational innovations
BioCentury | Aug 30, 2023
Discovery & Translation
Midnolin-proteasome pathway; plus inhibitory receptor on T cells and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 131